Latest news
Immunocore (IMCR) Stock Nears Breakeven While KIMMTRAK Risk Still Dominates - simplywall.stsimplywall.st · Sat, 08 Aug 2026 04:44:03 GMTMorgan Stanley Maintains Immunocore(IMCR.US) With Hold Rating, Raises Target Price to $43 - MoomooMoomoo · Fri, 07 Aug 2026 20:49:13 GMTImmunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues - TradingViewTradingView · Fri, 07 Aug 2026 17:27:00 GMTWall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Zacks Investment ResearchZacks Investment Research · Fri, 07 Aug 2026 13:02:14 GMTImmunocore (NASDAQ:IMCR) Rating Increased to Strong-Buy at Zacks Research - MarketBeatMarketBeat · Fri, 07 Aug 2026 11:33:44 GMTIMCR SWOT Analysis: Growth Potential Amidst Financial Challenges Revealed in 10-Q Filing - GuruFocusGuruFocus · Fri, 07 Aug 2026 06:48:48 GMTImmunocore Holdings plc 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-08-07 - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 05:13:27 GMTImmunocore Holdings Q2 2026 Earnings Call Highlights - Intellectia AIIntellectia AI · Thu, 06 Aug 2026 23:55:11 GMT